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Summary
Background—On April 25, 2017, a cluster of unexplained illnesses and deaths associated with a 
funeral was reported in Sinoe County, Liberia. Molecular testing identified Neisseria meningitidis 
serogroup C (NmC) in specimens from patients. We describe the epidemiological investigation of 
this cluster and metagenomic characterisation of the outbreak strain.
Methods—We collected epidemiological data from the field investigation and medical records 
review. Confirmed, probable, and suspected cases were defined on the basis of molecular testing 
and signs or symptoms of meningococcal disease. Metagenomic sequences from patient 
specimens were compared with 141 meningococcal isolate genomes to determine strain lineage.
Findings—28 meningococcal disease cases were identified, with dates of symptom onset from 
April 21 to April 30, 2017: 13 confirmed, three probable, and 12 suspected. 13 patients died. Six 
(21%) patients reported fever and 23 (82%) reported gastrointestinal symptoms. The attack rate for 
confirmed and probable cases among funeral attendees was 10%. Metagenomic sequences from 
six patient specimens were similar to a sequence type (ST) 10217 (clonal complex [CC] 10217) 
isolate genome from Niger, 2015. Multilocus sequencing identified five of seven alleles from one 
specimen that matched ST-9367, which is represented in the PubMLST database by one carriage 
isolate from Burkina Faso, in 2011, and belongs to CC10217.
Interpretation—This outbreak featured high attack and case fatality rates. Clinical presentation 
was broadly consistent with previous meningococcal disease outbreaks, but predominance of 
gastrointestinal symptoms was unusual compared with previous African meningitis epidemics. 
The outbreak strain was genetically similar to NmC CC10217, which caused meningococcal 
disease outbreaks in Niger and Nigeria. CC10217 had previously been identified only in the 
African meningitis belt.
Introduction
Meningococcal disease, caused by Neisseria meningitidis, is life-threatening and often 
presents as meningitis, with symptoms including fever, headache, stiff neck, and altered 
mental status. N meningitidis can also cause bloodstream infection, or meningococcaemia, 
which manifests with non-specific symptoms such as fever, vomiting, fatigue, and diarrhoea; 
Bozio et al. Page 3
Lancet Infect Dis. Author manuscript; available in PMC 2019 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
petechiae or, in later stages, a characteristic purpuric rash can also be present. 
Meningococcal disease progresses rapidly, with 9–12% of meningitis cases and up to 40% 
of meningococcaemia cases being fatal despite prompt antibiotic treatment.1
Globally, the highest incidence of meningococcal disease is in the meningitis belt in sub-
Saharan Africa, which stretches from Senegal to Ethiopia and has annual seasonal 
meningitis outbreaks, with large-scale epidemics occurring every 8–12 years.2 N 
meningitidis serogroup A, one of 12 meningococcal serogroups, caused most of the 
outbreaks within the meningitis belt countries before 2010.3,4 With introduction of the 
meningococcal serogroup A conjugate vaccine in 2010, serogroup A outbreaks have been 
nearly eliminated, and N meningitidis serogroups C, W, and X have become the 
predominant causes of meningococcal disease.3,4
Meningococcal strains are further classified into sequence types (STs) and clonal complexes 
(CCs) by use of multilocus sequence typing (MLST). Between 2010 and 2013, the common 
CCs encountered in Africa were CC11 (mainly associated with serogroup W) and CC181 
(serogroup X).4,5 In 2013, a novel N meningitidis serogroup C (NmC) CC10217 strain 
emerged in Nigeria, causing the first reported outbreak of NmC in the meningitis belt since 
1979.3 Since then, Nigeria and Niger have had multiple meningitis outbreaks due to 
CC10217, including epidemics of close to 10 000 suspected cases in Niger in 2015.6,7 
Further expansion of this epidemic-associated CC is a substantial public health concern, 
particularly in light of global shortages of serogroup C-containing vaccines for outbreak 
response in Africa.
On April 25, 2017, a cluster of 14 unexplained illnesses and eight deaths associated with a 
funeral was reported in Liberia.8 Liberia is not located in the meningitis belt, but borders 
two meningitis belt countries, Guinea and Côte d’lvoire. By May 7, 31 cases with 13 deaths 
were reported. The initial differential diagnosis was broad and included Ebola virus disease, 
because Liberia had been affected by the 2014–15 Ebola virus epidemic. However, 
molecular testing of four specimens from patients at the US Centers for Disease Control and 
Prevention (CDC) headquarters (Atlanta, GA, USA) identified NmC as the causative agent 
of the illness cluster. In this outbreak report, we describe the epidemiological and laboratory 
findings from this cluster of initially unexplained illnesses in Liberia and the metagenomic 
analysis done to identify the cause of the outbreak.
Methods
Field investigation
The unexplained cluster of illnesses and deaths was initially detected through community 
event-based surveillance, in which community workers identify signs and symptoms of 
priority diseases or unusual events. After notification of the cluster by Liberia’s Sinoe 
County Health Team on April 25, 2017, a county-led field investigation and response was 
immediately launched with support from the National Rapid Response Team and 
epidemiologists from the CDC, WHO, and the African Field Epidemiology Network, from 
April 26 to May 27.8
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An outbreak case was defined as a person who had visited or lived in Sinoe County 
(population 102 391; appendix) and presented with two or more symptoms, including 
headache, vomiting, mental confusion, and weakness, with illness onset on or after April 10, 
2017. Patients and their families were interviewed by surveillance officers by use of a 
questionnaire to gather demographic information, food and environmental exposures, 
clinical features and timing of illness, and contacts with or knowledge of any other people 
who were or had been recently ill. Clinical information was also extracted from medical 
records. Active case finding was done in the community and health facilities to identify 
additional cases and their close contacts at Sinoe County clinics and the county’s sole 
hospital, which served as the referral health facility. Epidemiological links among cases 
were identified on the basis of contacts reported in the case investigation form or from 
patient and family member interviews. Epidemiological investigation forms, medical 
records, and notes from the field investigators were reconciled to generate the final dataset.
Laboratory confirmation of the outbreak and molecular characterisation of specimens
Haematology and blood chemistry testing were done at local laboratories, whereas Ebola 
and Lassa virus testing were done at the National Reference Laboratory in Liberia by reverse 
transcriptase PCR. Food samples were screened for toxins at the University of Natural 
Resources and Life Sciences (Vienna, Austria) by use of a high performance liquid 
chromatography-tandem-mass spectrometry-based multi-mycotoxin method.9 A forensic 
pathologist did two autopsies.
Testing for metals10 and organophosphates,11 as well as multipathogen screening with a 
quantitative PCR-based assay called TaqMan array card (TAC), which simultaneously 
screens for 23 respiratory pathogens, was done at the CDC. We used tier 1 and tier 2 TAC 
assays12 with a modified bead beating protocol to screen specimens for multiple disease 
causes. Direct real-time PCR (rtPCR) was done in specimens sent to the CDC and in 
additional specimens in Liberia to confirm the pathogen and serogroup.13
We selected specimens with abundant N meningitidis DNA for molecular characterisation. 
We used Sanger sequencing14 for MLST analysis and metagenomic sequencing for strain 
similarity analyses.13 For meta-genomic analysis, DNA was sequenced on an MiSeq system 
(Illumina, San Diego, CA, USA), and N meningitidis reads were identified with k-SLAM15 
(version 1.0; appendix). The metagenomic N meningitidis reads were mapped to the FAM18 
N meningitidis reference genome16 and compared with a genome alignment of 141 diverse 
N meningitidis isolates from the CDC isolate collection; the genome alignment of these 
isolates was also generated by mapping reads to the FAM18 reference genome. We 
calculated similarity between the metagenomic reads and each of the 141 isolate genomes at 
polymorphic positions, defined as positions in the core genome alignment where the 
consensus base call differed among the isolate genomes. The accuracy of similarity 
estimates calculated by this method was assessed by subsampling from whole genome 
sequence data (appendix).
Bozio et al. Page 5
Lancet Infect Dis. Author manuscript; available in PMC 2019 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Refined case definitions
The outbreak case definition was refined after laboratory testing confirmed the causative 
agent of the cluster. A confirmed case of meningococcal disease was defined as detection of 
NmC by rtPCR in any specimen from an outbreak case. A probable case was defined as the 
presence of purpura, detection of N meningitidis that was non-groupable in a sterile site 
specimen, or sudden death accompanied by at least three symptoms of meningococcaemia or 
meningitis, including documented fever, vomiting, diarrhoea, cold extremities, joint pain, 
muscle pain, chest pain, abdominal pain, neck stiffness, altered consciousness, headache, 
and convulsions. A suspected case was defined as the presence of three or more of these 
symptoms, but without meeting the confirmed or probable case definition. An outbreak case 
that did not meet the suspected case definition was defined as not having meningococcal 
disease; these cases were excluded from the analysis.
Statistical methods
We compared characteristics of confirmed and probable cases with those of suspected cases 
with χ2 test or Fisher’s exact test. Differences in median were tested with the Mann-
Whitney test. A p value less than 0·05 was considered statistically significant. We calculated 
an attack rate for meningococcal disease by dividing the number of confirmed and probable 
meningococcal disease cases among people who attended the funeral by the estimated 
number of funeral attendees. Analyses were done with Epi Info (version 7·2) and SAS 
(version 9.4).
The full investigation was determined by the CDC to be a public health disease control 
activity and did not require review by an institutional review board.
Role of the funding source
The sponsor of the study had no role in design of the investigation, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all the data in the investigation and had final responsibility for the decision to 
submit for publication.
Results
Approximately 150 people attended the funeral events (funeral, wake, and repast) on April 
21–22, 2017. 31 disease cases were identified as part of the cluster by use of the outbreak 
case definition: 29 had attended the funeral, one was a close contact of a funeral attendee, 
and one had a meal with a driver who travelled from Sinoe County. No other suspected 
meningitis cases were reported in Sinoe County before or during the funeral events. 28 of 31 
cases were classified as cases of meningococcal disease: 13 were classified as confirmed 
cases, three as probable, and 12 as suspected. The remaining three initially identified cases 
were not cases of meningococcal disease. Among the 28 meningococcal disease cases, most 
were reported from Sinoe County, about half were female, and half were aged 10–19 years 
(table 1). No meningococcal disease cases were reported in children younger than 10 years. 
By contrast, among the 61 other funeral attendees for whom age was available, five (8%) 
were younger than 10 years, 11 (18%) were aged 10–19 years, six (10%) were aged 20–29 
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years, 11 (18%) were aged 30–39 years, nine (15%) were aged 40–49 years, and 19 (31%) 
were 50 years or older. No patients reported recent travel outside of Liberia. The dates of 
symptom onset ranged from April 21 to April 30, 2017, with 20 (71%) patients reporting 
onset on April 23–24 (figure 1). Although 16 cases were reclassified as confirmed and 
probable, 15 of these had attended the funeral, resulting in an attack rate of 10% among 
approximately 150 funeral attendees.
Predominant signs and symptoms of disease were weakness, headache, gastrointestinal 
symptoms (23 [82%] of 28 reported vomiting or diarrhoea), and abdominal pain; 
documented fever (based on temperature measurement) was uncommon (table 1). The 
clinical presentation was broadly similar when comparing confirmed and probable cases 
with suspected cases. However, purpura, convulsions, and cold extremities were reported 
only among confirmed and probable cases (table 1). Purpura was part of the probable case 
definition, whereas convulsions are consistent with late stages of meningitis and cold 
extremities with late stages of meningococcaemia. Autopsies done on two fatal confirmed 
cases that occurred in Montserrado County had findings consistent with meningococcal 
disease.
All meningococcal disease cases were admitted to a hospital or dead upon arrival at the 
hospital (table 1), with the exception of two suspected cases, who refused to be hospitalised. 
Additionally, the median time between date of onset and hospital admission (including 
deaths upon arrival at hospital) was significantly lower in confirmed and probable cases than 
in suspected cases (p=0·0002; table 1). Among all 28 cases, 13 (46%) patients died. The case 
fatality rate of confirmed and probable cases was significantly higher than that of suspected 
cases (p=0·0001; table 1). Of the 13 fatal cases, four patients were dead on arrival at the 
hospital and did not receive antibiotics. The remaining nine patients were admitted to a 
hospital, and seven received antibiotics. Furthermore, of the 17 patients who had blood, 
plasma, or cardiac blood specimens collected, ten were bacteraemic (seven died), and seven 
were not bacteraemic (all seven survived).
Among the 28 meningococcal disease cases, 17 (61%) patients reported contacts with one or 
more patients (figure 2). Five confirmed cases had close contact with one or more patients 
who had earlier onsets; all five patients reported symptom onset more than 24 h (1–5 days) 
after symptom onset of the patient, or patients, with whom they had close contact.
At the start of the outbreak, samples were not collected systematically for all cases because 
the cause and scope of the outbreak was unknown. Haematology tests, chemistry tests, or 
both were done on specimens from 12 cases; no consistent abnormalities were identified to 
guide determination of outbreak cause. All specimens tested for Ebola and Lassa virus by 
PCR (n=23) were negative. Toxicology testing of urine (n=3) and food (n=10) specimens did 
not detect sufficient amounts of any toxin to explain the outbreak.
63 clinical specimens from 24 of 31 cases, including 24 specimens from the two autopsies, 
were available for testing. Six specimens from four cases were tested by TAC, and N 
meningitidis was detected in all six specimens. We did N meningitidis serogroup-specific 
rtPCR on the same six specimens and one additional oral swab specimen—from one of the 
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same four cases—and confirmed that all specimens were positive for NmC. Analyses with 
rtPCR detected N meningitidis in 40 (63%) of 63 specimens; 39 of these 40 specimens 
tested positive for NmC (98%) and one for non-groupable N meningitidis (2%), which was 
negative for invasive serogroups A, B, C, W, X, and Y. Overall, we detected N meningitidis 
in 14 of 24 cases with available specimens, of which 11 cases had positive specimens from 
sterile sites. Of the 13 patients who died, 11 had specimens tested; all were positive for NmC 
(table 2).
We selected eight specimens from six cases, including cardiac blood, plasma, blood, urine, 
and vitreous humour fluid, with abundant N meningitidis DNA for molecular 
characterisation. All eight specimens were analysed by metagenomic sequencing, and one 
blood specimen was tested by MLST analysis. Metagenomic sequencing identified 340–
4374 N meningitidis DNA fragments in each specimen. Specimens from patient one (blood) 
and patient three (plasma) were excluded from further analysis because of insufficient reads. 
For each patient, N meningitidis reads, from the specimen with most reads, were compared 
with a reference collection of 141 diverse N meningitidis genomes representing 140 
sequence types, with more than 0·5% genetic variation between each pair of genomes 
(appendix). N meningitidis DNA sequence similarity between the references and the 
specimens ranged from 79% (3860 of 4863) to 99% (7704 of 7763) when assessed at all 
polymorphic positions where reads for a given specimen were mapped (86 739 total 
positions, range 4412–59 485 positions per specimen; figure 3). For all specimens tested, N 
meningitidis DNA sequences were most similar to the genome of an ST-10217 NmC isolate 
obtained during the 2015 epidemic in Niger.7 N meningitidis DNA sequences from five 
specimens had more than 98% (>4351 of 4412) similarity to the ST-10217 genome, and one 
specimen (case 4, figure 3) had 91% (4449 of 4863) similarity. By contrast, N meningitidis 
DNA sequences had less than 87% (<4229 of 4863) similarity to any other genome in the 
reference collection.
Only one specimen was successfully analysed by MLST, with five of seven MLST genes 
identified. In PubMLST, the only sequence type that contains the five alleles identified in the 
patient specimen is ST-9367, which was identified from a non-groupable carriage isolate 
obtained from Burkina Faso in 2011. ST-9367 whole genome sequencing data were not 
available for comparison by the metagenomics method. Four of five alleles identified in the 
outbreak specimen were also present in ST-10217. Both ST-10217 and ST-9367 belong to 
CC10217 and are similar, with MLST profiles that differ by only one nucleotide in fumC 
(appendix).
Discussion
During and after the 2014–15 Ebola epidemic, the Liberian Ministry of Health and 
international partners made substantial investments in strengthening Liberia’s surveillance 
and laboratory capacity for outbreak response.17,18 These efforts enabled prompt detection 
and notification of this cluster, rapid rule-out of Ebola and Lassa viruses, and immediate 
implementation of infection control and contact tracing procedures during this outbreak. 
Although the predominance of gastrointestinal symptoms prompted initial concerns about 
toxic exposure, thorough laboratory analyses and indepth case investigations led to diagnosis 
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and confirmation of meningococcal disease. After confirmation of the outbreak cause on 
May 16, 2017, the administration of antibiotic chemoprophylaxis (ciprofloxacin) was 
attempted to funeral attendees and contacts of cases, by use of Liberia’s contact tracing 
infrastructure. Because of the absence of ongoing meningococcal transmission over several 
weeks, vaccination was not implemented.
In the past several years, multiple NmC outbreaks in the meningitis belt have been 
associated with CC10217, including a 2013 outbreak in Nigeria6 and large-scale outbreaks 
in Niger and Nigeria in 2015.7 Our molecular analysis identified the Liberia outbreak strain 
as being most similar to strains from CC10217. Although we were unable to completely 
define the sequence type of the Liberia outbreak strain, the detection of an outbreak with an 
NmC strain that is a member of CC10217 is concerning in a region where NmC is emerging 
and the population is unlikely to have immunity to NmC. The introduction of a strain from 
an epidemic-associated CC might have contributed to the unusually high attack rate among 
funeral attendees observed in this outbreak.19 The spread of this strain highlights the 
potential for global transmission of meningococcal strains from the African meningitis belt, 
as shown by the worldwide meningococcal disease outbreak after the Hajj, in 2000.20
In CC10217 meningococcal disease outbreaks of the past decade, reported symptoms have 
been unremarkable;21 however, this Liberia outbreak featured a predominance of 
gastrointestinal symptoms. Although gastrointestinal symptoms are consistent with 
meningococcal disease, cases with primarily gastrointestinal symptoms have been 
considered rare.2,22 However, gastrointestinal symptoms have been described as a more 
common symptom of meningococcal disease, particularly among NmW ST-11 cases in the 
UK23 and Chile.24 Notably, among NmW cases with gastrointestinal symptoms in the UK, 
71% (five of seven) died within 24 h of presentation,23 similar to the rapid disease 
progression observed in this outbreak. Similarly, diarrhoea was significantly associated with 
death in the NmW ST-11 outbreak in Chile.24 The potential human or bacteriological factors 
contributing to the emergence of meningococcal disease with predominantly gastrointestinal 
symptoms are unclear.
In addition to the high prevalence of gastrointestinal symptoms, the tight temporal clustering 
of cases, low prevalence of documented fever, and rapid disease progression initially led to 
suspicions of a toxic cause for the outbreak. However, these features are also consistent with 
meningococcal disease. The temporal clustering of cases, mimicking a point source 
exposure, has been observed in some previous meningococcal disease outbreaks.25,26 
Although fever is typically among the most common meningococcal disease symptoms, 
absence of documented fever was noted in 40% (24 of 60) of cases in a 2012 NmW ST-11 
outbreak in Chile24 and has been observed in septic patients.27 This observation might 
account for the absence of documented fever among the patients in this outbreak who died 
on arrival at the hospital or within hours of presenting to care. Given the rapidity with which 
meningococcal disease can progress to overwhelming sepsis, the absence of fever does not 
rule out meningococcal disease, particularly when purpura or other symptoms characteristic 
of meningococcal disease are also noted.
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Although meningitis has historically been the primary presentation of meningococcal 
disease in the meningitis belt, the majority of patients in this outbreak presented with 
meningococcaemia, including five patients with purpura. Along with late presentation to 
care, this difference in reported disease presentations might help to explain the very high 
case fatality rate in this outbreak compared with previous reports of cases in the meningitis 
belt.21 Although climatic or other differences between Liberia and countries in the 
meningitis belt could affect the predominant presentation of meningococcal disease in these 
areas, there are few data on the prevalence of meningococcaemia in the meningitis belt, 
because blood is not routinely drawn or tested for meningococcal detection. However, NmC 
infection in other areas of the world frequently presents as meningococcaemia (CDC, 
unpublished data).28 With the emergence of NmC as the predominant cause of 
meningococcal disease in the African meningitis belt, meningococcaemia, particularly with 
purpura, must be recognised by clinicians and public health professionals in the region as a 
potential presentation of meningococcal disease.
The spread of NmC CC10217 to Liberia and throughout the meningitis belt shows that the 
emergence, expansion, and spread of a novel meningococcal clone continues to have the 
potential to cause devastating outbreaks. Although NmA epidemics have been largely 
eliminated after the introduction of meningococcal serogroup A conjugate vaccine, the NmC 
outbreaks within and outside the meningitis belt highlight the need to address global 
shortages of serogroup C-containing vaccines to ensure an adequate supply for future 
outbreak responses. Sustained investment in global health security to strengthen prevention, 
detection, and response to infectious disease threats—as epitomised by Liberia’s successful 
improvements in disease surveillance, laboratory systems, workforce development, and 
emergency operations after the Ebola virus epidemic— might also provide benefits in 
tracking and controlling the spread of CC10217 and related strains. Continued strengthening 
of public health surveillance and laboratory capacity in Africa, as well as networking with 
reference laboratories, will also facilitate outbreak detection and implementation of 
appropriate response measures.
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Research in context
Evidence before this study
We searched PubMed for English-language articles published from database inception to 
Dec 1, 2017, regarding outbreaks of meningococcal disease with search terms including 
“Neisseria meningitidis”, “Neisseria meningitidis serogroup C”, “meningococcal”, 
“Africa”, “epidemic”, “outbreak”, and “meningitis”. We reviewed these articles and 
others citing or cited by the articles retrieved. Outbreaks of N meningitidis serogroup C 
(NmC) clonal complex (CC) 10217 were first reported in Nigeria in 2013, and in Niger in 
2015, both of which lie in the meningitis belt. Few meningococcal disease outbreaks have 
been previously reported in Africa outside of the meningitis belt. Although 
gastrointestinal symptoms are consistent with meningococcal disease, they have rarely 
been identified as predominant presenting symptoms. However, in the past several years, 
they have been recognised as a more common symptom of meningococcal disease.
Added value of this study
We describe the epidemiological investigation of an unusual meningococcal disease 
outbreak in Liberia and the metagenomic characterisation of the NmC outbreak strain. Of 
the 31 cases identified as part of the initial cluster of unknown illness, 13 were confirmed 
meningococcal disease cases and three were probable. Most patients presented with 
predominantly gastrointestinal symptoms and only six had documented fever; however, 
five had purpura. Metagenomic analysis revealed that the outbreak strain was genetically 
similar to the NmC CC10217 strain that caused the meningococcal disease epidemics in 
Nigeria in 2013, and in Niger in 2015. Gastrointestinal symptoms or absence of fever 
should not be considered to rule out meningococcal disease, particularly when purpura is 
present. This NmC outbreak shows that the emergence, expansion, and spread of a novel 
meningococcal clone continues to have the potential to cause devastating outbreaks.
Implications of all the available evidence
With the emergence of serogroup C as an important cause of meningitis outbreaks within 
and outside the African meningitis belt, clinicians and public health professionals should 
be aware that the disease might present as either meningitis or meningococcaemia, and 
symptoms of meningococcaemia, particularly purpura, should be recognised. Continued 
strengthening of public health surveillance and laboratory capacity in Africa, as well as 
networking with reference laboratories, is crucial to ensure that outbreaks are rapidly 
detected and appropriate response measures are implemented. The NmC outbreaks in the 
past several years, within and outside the meningitis belt, highlight the need to address 
global shortages of serogroup C-containing vaccines to ensure an adequate supply for 
future outbreak response.
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Figure 1: Cases of meningococcal disease by date of onset
Data are from 28 cases. Of the 31 outbreak cases, three were considered not cases of 
meningococcal disease and were excluded.
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Figure 2: Reported contacts among cases
17 cases with any reported contact with other cases are shown. Each circle represents a case; 
a line between circles indicates contact between cases with the weight of the line illustrating 
the type of contact. Circles are coloured on the basis of case classification, and size of circle 
is based on number of additional cases with whom contact was reported. Nm=Neisseria 
meningitidis.
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Figure 3: Metagenomic analysis from six non-oral specimens with high abundance of Neisseria 
meningitidis DNA
Similarity of 141 N meningitidis isolate genomes to the N meningitidis sequences identified 
in specimens from each of six cases. Metagenomic datasets are labelled with the case 
identifier, the source of the specimen, and the number of polymorphic positions within the 
alignment of 141 isolate genomes for which the specimen sequences had a single base call. 
The percentage similarity to each of the 141 isolate genomes is plotted for each specimen; a 
boxplot shows the first, second, and third quartiles, and error bars cover points beyond the 
first or third quartile, up to 1·5 times the IQR. Outliers above the whiskers are labelled with 
the sequence type (ST) of the isolate.
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Table 1:
Characteristics of 28 meningococcal disease cases overall and by case status
Overall (n=28) Confirmed and probable 
(n=16)
Suspected (n=12)
Case status
 Confirmed 13 (46%) 13 (81%) 0 (0%)
 Probable 3 (11%) 3 (19%) 0 (0%)
 Suspected 12 (43%) 0 (0%) 12 (100%)
Sex
 Female 15 (54%) 11 (69%) 4 (33%)
 Male 13 (46%) 5 (31%) 8 (67%)
County of residence
 Sinoe 24 (86%) 14 (88%) 10 (83%)
 Montserrado 2 (7%) 2 (13%) 0 (0%)
 Grand Bassa 2 (7%) 0 (0%) 2 (17%)
Age (years)
 10–19 14 (50%) 10 (63%) 4 (33%)
 20–29 7 (25%) 3 (19%) 4 (33%)
 30–39 0 (0%) 0 (0%) 0 (0%)
 40–49 3 (11%) 0 (0%) 3 (25%)
 ≥50 4 (14%) 3 (19%) 1 (8%)
Attended ≥1 funeral events (funeral, wake, and repast) 26 (93%) 15 (94%) 11 (92%)
Signs and symptoms
 Weakness 26 (93%) 15 (94%) 11 (92%)
 Abdominal pain 22 (79%) 11 (69%) 11 (92%)
 Any other body pain 8 (29%) 5 (31%) 3 (25%)
 Headache 24 (86%) 13 (81%) 11 (92%)
 Any gastrointestinal symptoms 23 (82%) 12 (75%) 11 (92%)
  Vomiting 20 (71%) 10 (63%) 10 (83%)
  Diarrhoea 16 (57%) 8 (50%) 8 (67%)
 Any neurological signs 18 (64%) 11 (69%) 7 (58%)
  Confusion 15 (54%) 9 (56%) 6 (50%)
  Convulsions 4 (14%) 4 (25%) 0 (0%)
  Hallucinations 4 (14%) 3 (19%) 1 (8%)
  Any other neurological signs 6 (21%) 4 (25%) 2 (17%)
 Any respiratory signs 7 (25%) 4 (25%) 3 (25%)
 Documented fever 6 (21%) 3 (19%) 3 (25%)
 Purpura 5 (18%) 5 (31%) 0 (0%)
 Cold extremities 2 (7%) 2 (13%) 0 (0%)
Hospitalisation
 Admitted 22 (79%) 12 (75%) 10 (83%)
 Dead upon arrival at hospital 4 (14%) 4 (25%) 0 (0%)
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Overall (n=28) Confirmed and probable 
(n=16)
Suspected (n=12)
 Community* 2 (7%) 0 (0%) 2 (17%)
Received antibiotics 19 (68%) 10 (63%) 9 (75%)
Died 13 (46%) 12 (75%) 1 (8%)
Median time between date of onset and hospital admission†, in days 
(IQR)
2 (1–4) 1–5 (1–2) 6–5 (3–9)
Median timing between date of onset and death, in days (IQR) 1 (1–2) 1 (1–2) 4 (4–4)
Data are n (%), unless stated otherwise.
*
Patients did not present to a hospital.
†
Hospital admission includes patients who were dead upon arrival at the hospital.
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